Our findings offer an alternative hypothesis: HHLA2 may act as a co-stimulatory ligand in ovarian cancer, and the absence of HHLA2 expression may contribute to the establishment of an immunosuppressive tumour microenvironment and tumour progression. This evidence concerns the gene HHLA2 and ovarian carcinoma.